John Durocher - 16 Nov 2025 Form 3 Insider Report for CALIX, INC (CALX)

Role
COO
Signature
/s/ Tom Gemetti as Attorney-in-Fact for John Durocher
Issuer symbol
CALX
Transactions as of
16 Nov 2025
Net transactions value
$0
Form type
3
Filing time
25 Nov 2025, 17:44:36 UTC
Next filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Durocher John COO C/O CALIX, INC., 3155 OLSEN DRIVE, SUITE 450, SAN JOSE /s/ Tom Gemetti as Attorney-in-Fact for John Durocher 25 Nov 2025 0002098235

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding (CALX) Common Stock 1,928 16 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding (CALX) Stock Option (right to buy) 16 Nov 2025 Common Stock 200,000 $51.83 Direct F1
holding (CALX) Stock Option (right to buy) 16 Nov 2025 Common Stock 42,555 $51.83 Direct F2
holding (CALX) Stock Option (right to buy) 16 Nov 2025 Common Stock 107,775 $34.26 Direct F3
holding (CALX) Stock Option (right to buy) 16 Nov 2025 Common Stock 56,350 $34.26 Direct F4
holding (CALX) Stock Option (right to buy) 16 Nov 2025 Common Stock 195,000 $39.68 Direct F5
holding (CALX) Stock Option (right to buy) 16 Nov 2025 Common Stock 195,000 $39.68 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option grant vested on March 24, 2024, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 125,000 shares subject to the option grant are fully vested and exercisable.
F2 25% of the shares subject to the stock option grant vested on March 24, 2024, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 26,597 shares subject to the option grant are fully vested and exercisable.
F3 25% of the shares subject to the stock option grant vested on February 8, 2025, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 47,151 shares subject to the option grant are fully vested and exercisable.
F4 25% of the shares subject to the stock option grant vested on February 8, 2025, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 17,622 shares subject to the option grant are fully vested and exercisable.
F5 25% of these stock options will vest on the first anniversary of the grant date. Thereafter, the remainder of these stock options will vest quarterly in substantially equal installments over the next 36 months, subject to Reporting Person's continued service through each vesting date.
F6 The nonqualified stock option award shall vest: (i) as to 25% of the shares of common stock subject to the stock option award, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the stock option award, quarterly in equal installments over 36 months from January 31, 2026, subject to the reporting person's continued employment with Calix through the applicable vesting dates.